

Cardiovascular Intelligence Report

Heart Failure · AFib · Stroke · Cardiometabolic · Vision 2030

● LIVE INGEST

Last refresh — 07 May 2026 21:43:39Z

Window — last 90 days

Pipeline — tools/scout-ingest

<p>TRACKED SIGNALS</p> <p>1,710</p> <p>Public, source-cited</p>	<p>SOURCES ACTIVE</p> <p>4 / 6</p> <p>Of 6 wired</p>	<p>COMPANIES MONITORED</p> <p>50</p> <p>Atlas-linked dossiers</p>	<p>CRITICAL / HIGH</p> <p>174</p> <p>Material signals (90d)</p>
--	---	--	--

RISK REGISTER · THE COST OF SEEING LATE Adversarial verification scope

Three exposures every cardiovascular portfolio carries today.

Reimbursement Cycle Risk

Heart-failure, SGLT2, ARNI, and anticoagulant coverage decisions in flight across the current CMS LCD cycle reshape roughly \$40B in run-rate revenue. Live PubMed and CMS LCD signals are tracked across the indexer.

1,000

Readmission Risk

CMS HRRP imposes 30-day readmission penalties on heart-failure populations. Hospital-system exposure compounds across every payer relationship without remote monitoring infrastructure.








CALIBRATING · NEXT REFRESH

Sovereign Procurement Risk

King Faisal Cardiac Institute, Cleveland Clinic Abu Dhabi, and Hikma cardiovascular under continuous monitoring. Vision 2030 cardiac procurement windows close on a defined cycle — missing one means missing a cycle.

3 / 50

What we are watching

FDA openFDA		333
ClinicalTrials.gov		217
PubMed		1000
SEC EDGAR		160
CMS LCD		0
USPTO Patents		0
Manufacturer Pipelines		0

Top 10 by severity and recency

PUBMED CRITICAL 2026-05-04

Comprehensive pathological and genetic investigation of four young adults with a short QT interval and sudden unexpected death.

Hata Y

Comprehensive pathological and genetic investigation of four young adults with a short QT interval and sudden...

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-05-04

Refining sudden cardiac death risk in hypertrophic cardiomyopathy: The interplay between atrial and ventricular arrhythmias.

Kukuev A

Refining sudden cardiac death risk in hypertrophic cardiomyopathy: The interplay between atrial and ventricul...

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-05-03

The role of global longitudinal strain in predicting fatal arrhythmic events in hypertrophic cardiomyopathy: An up-to-date systematic review and Meta-analysis.

Bazoukis G

The role of global longitudinal strain in predicting fatal arrhythmic events in hypertrophic cardiomyopathy: An up-...

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-01-01

Place of Death, Care Intensity, Symptom Prevalence, and Symptom Management for Patients With Stroke at End-of-Life.

Place of Death, Care Intensity, Symptom Prevalence, and Symptom Management for Patients With Stroke at End-of-...

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-01-01

Comprehensive Options for Pediatric Donation After Circulatory Death Donors.

Kucera JA

Comprehensive Options for Pediatric Donation After Circulatory Death Donors.

[PubMed \(NCBI E-utilities\) ↗](#)

CLINICALTRIALS CRITICAL 2020-10-12

Hibernating Myocardium and Sudden Cardiac Death

State University of New York at Buffalo

The hypothesis of PAREPET is that hibernating myocardium (viable myocardium with reduced resting flow) and/or viabl...

[ClinicalTrials.gov ↗](#)

FDA

CRITICAL

2016-08-17

HeartWare Ventricular Assist System (HVAD), US product: Model No.: I103; and International Product: Model No.: I104XX. Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. Designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter.

HeartWare, Inc

Foreign material found within the driveline connector of the HVAD Pump that could cause increased impedance resultin...

U.S. Food & Drug Administration >

FDA

CRITICAL

2016-06-08

HeartWare Ventricular Assist System Controller Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. The HVAD is designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter

Heartware, Inc.

Loose connector ports in controller body.

U.S. Food & Drug Administration >

FDA

CRITICAL

2009-09-22

Penumbra Neuron Delivery Catheter 070, percutaneous catheter, catalog numbers PND6F070I058, PND6F070956, PND6F070I058M, and PND6F070956M; manufactured by Penumbra, Inc., Alameda, CA. Indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.

Penumbra Inc.

Failure-- product can kink or ovalize, which may result in difficulty in catheter advancement or delivery of other...

U.S. Food & Drug Administration >

SEC

HIGH

2026-05-07

LXRX — 8-K filing

LXRX

8-K

SEC EDGAR >

Reimbursement watchlist

CMS & FORMULARY COVERAGE · ACTIVE CYCLE

Heart-failure, ARNI, SGLT2, and anticoagulant coverage decisions are reshaping the cardiovascular economics base.

Coverage and formulary decisions on ARNI therapy for HFref and HFpEF, SGLT2 inhibitors with cardiorenal indications, anticoagulant prescribing for AFib stroke prevention, and remote monitoring reimbursement for heart-failure populations are in active rewrite across CMS and the major commercial PBMs. AimwellBio's CMS LCD ingest is in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as the indexer comes online.

Saudi Arabia · GCC · Vision 2030

SOVEREIGN VECTOR · KSA / GCC / MENA

King Faisal Cardiac Institute and Cleveland Clinic Abu Dhabi anchor sovereign cardiac care across the Gulf. Vision 2030 has placed cardiovascular infrastructure inside an active procurement window.

The GCC + MENA cluster represents the highest-density sovereign-procurement opportunity for AimwellBio's cardiovascular intelligence layer. SFDA approvals, MOH formulary movements, and cross-border clinical infrastructure across Riyadh, Abu Dhabi, Dubai, Amman, and Cairo are already trackable through the indication-aware pipeline. Hikma Pharmaceuticals carries cardiovascular formulary depth across MENA.

Decisions of this scale — coverage policy, capital procurement of cardiac devices, ARNI and SGLT2 supply, AFib stroke-prevention programs, and heart-failure remote monitoring rollout — cannot rest on a single source or vendor pipeline page. They require an adversarial verification layer with origin URLs, fetch timestamps, and reproducible claims for every signal.

~18%

KSA diabetes-CV overlap, drives CV risk

3 / 50

Sovereign-tagged manufacturers monitored

\$200B+

Global cardiovascular category run-rate

7

Public sources triangulated per signal class

SOVEREIGN ROSTER · KSA / GCC / MENA

<p>King Faisal Cardiac Institute Riyadh, SA</p> <p>KSA</p>	<p>Cleveland Clinic Abu Dhabi Heart & Vascular Abu Dhabi, AE</p> <p>GCC</p>	<p>Hikma CV Amman, JO</p> <p>MENA</p>
---	--	--

Monitored issuers and operators

Cleveland Clinic Abu Dhabi Heart & Vascular Abu Dhabi, AE GCC	Hikma CV HIK Amman, JO MENA	King Faisal Cardiac Institute Riyadh, SA KSA
Abbott Cardiovascular ABT Abbott Park, IL MEDTECH	AliveCor Mountain View, CA EMERGING	Alnylam Pharmaceuticals ALNY Cambridge, MA BIOTECH
Arrowhead Pharmaceuticals ARWR Pasadena, CA BIOTECH	Asahi Intecc Nagoya, JP MEDTECH	AstraZeneca CV AZN Cambridge, UK BIGPHARMA
Bayer Cardiovascular Leverkusen, DE BIGPHARMA	BeiGene CV Pipeline BGNE Beijing, CN BIGPHARMA	Biotronik Berlin, DE MEDTECH
BIVACOR Cerritos, CA EMERGING	Boehringer Ingelheim CV Ingelheim, DE BIGPHARMA	Boston Scientific BSX Marlborough, MA MEDTECH
BridgeBio BBIO Palo Alto, CA BIOTECH	Bristol Myers Squibb CV BMY Princeton, NJ BIGPHARMA	Butterfly Network BFLY Burlington, MA EMERGING
Capricor Therapeutics CAPR San Diego, CA BIOTECH	Cardiol Therapeutics CRDL Oakville, ON, CA BIOTECH	Cleerly New York, NY EMERGING
Cleveland Clinic Heart Cleveland, OH EMERGING	Cordis Miami Lakes, FL MEDTECH	CVRx CVRX Minneapolis, MN MEDTECH
Cytokinetics CYTK South SF, CA BIOTECH	Daiichi Sankyo CV Tokyo, JP BIGPHARMA	Edwards Lifesciences EW Irvine, CA MEDTECH
Eko Health Oakland, CA EMERGING	Heartflow HTFL Mountain View, CA EMERGING	HeartFlow Redwood City, CA EMERGING

Humacyte HUMA Durham, NC EMERGING	Inari Medical NARI Irvine, CA EMERGING	Ionis Pharmaceuticals IONS Carlsbad, CA BIOTECH
iRhythm Technologies IRTC San Francisco, CA MEDTECH	Johnson & Johnson CV JNJ New Brunswick, NJ BIGPHARMA	Lexicon Pharmaceuticals LXX The Woodlands, TX BIOTECH
Mass General Brigham Heart Boston, MA EMERGING	Medtronic Cardiovascular MDT Minneapolis, MN MEDTECH	Merck CV Pipeline MRK Rahway, NJ BIGPHARMA
MicroPort Scientific Shanghai, CN MEDTECH	Novartis Cardiovascular NVS Basel, CH BIGPHARMA	Penumbra PEN Alameda, CA MEDTECH
Pfizer Cardiovascular PFE New York, NY BIGPHARMA	Sanofi Cardiovascular SNY Paris, FR BIGPHARMA	Stryker Cardiovascular SYK Kalamazoo, MI MEDTECH
Tenax Therapeutics TENX Chapel Hill, NC BIOTECH	Terumo CV Tokyo, JP BIGPHARMA	Texas Heart Institute Houston, TX EMERGING
Ultromics Oxford, UK EMERGING	Verve Therapeutics VERV Cambridge, MA BIOTECH	

06 - 90-DAY SIGNAL TIMELINE

Hover any bar for week detail

Volume & cadence of public disclosure



METHODOLOGY

This report is generated from a live ingest pipeline (`tools/scout-ingest`). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated 07 May 2026 21:43:39Z. Every signal carries source URL and fetch timestamp; click any card to view origin.

Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.

Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged companies (KSA, GCC, MENA) reflect publicly observable regional headquarters and institutional anchors; ministry-procurement detail is reserved for the partner intelligence surface.